uTREAT®

Curasight's primary focus is to advance uTREAT^® — a first-in-class radioligand therapy platform targeting uPAR, the functional driver of cancer aggressiveness across solid tumors. It is designed to eliminate aggressive cancer cells across multiple tumor types, including minimal residual disease, micro-metastases, and other lesions distant from the primary tumor. uTREAT^® is supported by uTRACE^®, our clinically validated uPAR PET diagnostic platform built on the same uPAR-targeting ligand. 

The advantage of targeted radioligand therapy compared with external beam radiation therapy

The principle and advantage of using targeted radioligand therapy (RLT) rather than conventional external beam radiation therapy is that RLT binds primarily to uPAR-expressing tumor tissue, enabling localized radiation delivery to uPAR-positive lesions, including small metastases, while minimizing irradiation of healthy tissue.

External beam radiation therapy irradiates the primary tumor and only a limited number of lesions from outside the body, while also significantly exposing healthy tissue to radiation, potentially causing side effects and long-term damage.

Using a peptide as the ligand rather than antibodies

uTREAT^® is based on a small uPAR-binding peptide. The advantage is that peptides have a very short lifespan in the blood (less than ten minutes), meaning that uTREAT^® not bound to the tumor target is rapidly eliminated from the body. In contrast, antibodies remain in circulation for days, causing substantial and continued irradiation of healthy tissue.